The ID93 Tuberculosis Vaccine Candidate Does Not Induce Sensitivity to Purified Protein Derivative

Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis

(2014) S. Bertholet et al.   JOURNAL OF IMMUNOLOGY

The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine

(2012) S. L. Baldwin et al.   JOURNAL OF IMMUNOLOGY

Deciphering the proteome of the in vivo diagnostic reagent “purified protein derivative” from Mycobacterium tuberculosis

(2012) Yun Sang Cho et al.   PROTEOMICS

Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis

(2012) Shaobin Shang et al.   VACCINE

Assessment of vaccine testing at three laboratories using the guinea pig model of tuberculosis

(2011) Ajay Grover et al.   TUBERCULOSIS

The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices

(2011) Alice Zwerling et al.   PLOS MEDICINE

Three Protein Cocktails Mediate Delayed-Type Hypersensitivity Responses Indistinguishable from That Elicited by Purified Protein Derivative in the Guinea Pig Model ofMycobacterium tuberculosisInfection

(2010) Hongliang Yang et al.   INFECTION AND IMMUNITY

New vaccines for tuberculosis

(2010) Stefan HE Kaufmann et al.   LANCET

A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis

(2010) S. Bertholet et al.   Science Translational Medicine